Immunocore Holdings Business Summary

Immunocore Holdings plc (IMCR) is a commercial-stage biotechnology leader specializing in the development of T-cell receptor (TCR) bispecific immunotherapies through its proprietary ImmTAX (Immune mobilizing monoclonal TCRs Against X disease) platform. The company generates primary revenue through the global commercialization of KIMMTRAK (tebentafusp), the first-ever approved TCR therapy, indicated for HLA-A*02:01-positive metastatic uveal melanoma. Beyond its lead oncology product, Immunocore operates three distinct therapeutic segments: oncology (anchored by the PRAME-targeted brenetafusp franchise), infectious diseases (targeting HIV and HBV), and autoimmune diseases (including Type 1 diabetes). As of early 2026, the company maintains a dominant position in the soluble TCR bispecific market, competing directly with Adaptimmune Therapeutics, Iovance Biotherapeutics, and Moderna, while leveraging a robust cash position of approximately $864 million to fund multiple registrational Phase 3 trials. Leadership is spearheaded by CEO Bahija Jallal, PhD, the former President of MedImmune and Executive Vice President at AstraZeneca, who has overseen the company’s transition to a commercial entity since 2019. The executive team includes CFO Travis Coy, a former Eli Lilly M&A lead who joined in early 2025, and recently elevated Executive Vice Presidents Dr. Mohammed Dar (Clinical Development) and Mark Moyer (Regulatory and Quality), following a 2026 R&D restructuring. The company was founded by a distinguished scientific team including Bent Jakobsen, George Robinson, Nicholas Cross, and George Martin. Its governance is further bolstered by Board Chairman Professor Sir John Bell of Oxford University, with significant institutional backing from premier investors such as T. Rowe Price, Wellington Management, FMR LLC, and General Atlantic.